Ann: Investor Presentation, page-69

Another cracking preso which highlights the benefits of starting everything in AUS including R & D Expenditure etc. Cost conscious and clever.

We are valued at around a $53 mill market cap atm and miles in front of any competition.

I must remind punters that Pfizer bought out a company with one product in phase 3 for AD for 5 bill.

360 subjects are enrolled for BTX 1503 Phase 2 over 28 sites. That is simply mind blowing and a huge effort on behalf of the company.

Phase 2 for AD About to ramp up also, which will save costs to BOT by running two phase 2 trials concurrently. Again cash flow and cost conscious.

It might be a slow grind, now but in 6 - 12 months I am extremely confident in this little beauty. Price now is an absolute bargain imo.